FDA Vyleesi REMS Determination NDA 210557

FDA NDA 210557

FDA DRISK, FDA DBRUP

Summary

REMS was NOT necessary

Study Details

Study Design

Regulatory risk-management review

Indication

HSDD in premenopausal women

Intervention

1.75 mg SC

Species

Human